Overview
Non-small cell lung cancer (NSCLC) is the most common type of
lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of
the lungs or the cells lining the airways. Symptoms of lung cancer usually
occur in later stages of the disease. The signs and symptoms include persistent
cough that may get worse over time, trouble breathing or shortness of breath,
constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and
weakness and unintentional weight loss. The disease might be controlled with
the help of medications, chemotherapy and modifications in lifestyle.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555341-non-small-cell-lung-cancer-pipeline-review-h1-2017
Report
Highlights
The Pharmaceutical and Healthcare latest pipeline guide
Non-Small Cell Lung Cancer - Pipeline Review, H1 2017, provides comprehensive
information on the therapeutics under development for Non-Small Cell Lung
Cancer (Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases.
The Non-Small Cell Lung Cancer (Oncology) pipeline guide also
reviews of key players involved in therapeutic development for Non-Small Cell
Lung Cancer and features dormant and discontinued projects. Similarly, the
Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and
Discovery stages comprises 13, 11, 1, 40 and 4 molecules, respectively.
Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in
identifying and tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter strategies
to gain competitive advantage. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global
therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
Table of Contents
Introduction 13
Non-Small Cell Lung Cancer - Overview 14
Non-Small Cell Lung Cancer - Therapeutics Development 15
Non-Small Cell Lung Cancer - Therapeutics Assessment 84
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 118
Non-Small Cell Lung Cancer - Drug Profiles 278
Non-Small Cell Lung Cancer - Dormant Projects 2323
Non-Small Cell Lung Cancer - Discontinued Products 2343
Non-Small Cell Lung Cancer - Product Development Milestones 2351
Appendix 2369
Non-Small Cell Lung Cancer - Overview 14
Non-Small Cell Lung Cancer - Therapeutics Development 15
Non-Small Cell Lung Cancer - Therapeutics Assessment 84
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 118
Non-Small Cell Lung Cancer - Drug Profiles 278
Non-Small Cell Lung Cancer - Dormant Projects 2323
Non-Small Cell Lung Cancer - Discontinued Products 2343
Non-Small Cell Lung Cancer - Product Development Milestones 2351
Appendix 2369
List of Tables
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555341-non-small-cell-lung-cancer-pipeline-review-h1-2017
About Us
Wise Guy
Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium
progressive statistical surveying, market research reports, analysis &
forecast data for industries and governments around the globe. Wise Guy Reports
understand how essential statistical surveying information is for your
organization or association. Therefore, we have associated with the top
publishers and research firms all specialized in specific domains, ensuring you
will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner
Relations & Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208
133 9349 (UK)
No comments:
Post a Comment